Incidence and risk factors for post-ERCP pancreatitis in chronic pancreatitis

被引:40
|
作者
Zhao, Zhen-Hua [1 ,2 ]
Hu, Liang-Hao [1 ]
Ren, Hong-Bo [3 ]
Zhao, An-Jing [1 ]
Qian, Yang-Yang [1 ]
Sun, Xiao-Tian [1 ]
Su, Song [1 ]
Zhu, Shu-Guang [1 ]
Yu, Jin [1 ]
Zou, Wen-Bin [1 ]
Guo, Xiao-Rong [1 ]
Wang, Lei [1 ]
Li, Zhao-Shen [1 ]
Liao, Zhuan [1 ]
机构
[1] Second Mil Med Univ, Natl Clin Res Ctr Digest Dis, Shanghai Inst Pancreat Dis, Dept Gastroenterol,Digest Endoscopy Ctr,Changhai, Shanghai, Peoples R China
[2] Jining 1 Peoples Hosp, Dept Gastroenterol, Jining, Shandong, Peoples R China
[3] Shandong Univ, Qilu Hosp, Dept Gastroenterol, Jinan, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
M-ANNHEIM CLASSIFICATION; EUROPEAN-SOCIETY; COMPLICATIONS; SPHINCTEROTOMY; PROPHYLAXIS; MANAGEMENT;
D O I
10.1016/j.gie.2016.12.020
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims: Almost all studies on post-ERCP pancreatitis (PEP) have mainly involved patients with biliary diseases rather than chronic pancreatitis (CP), and the concept that CP seems to be a protective factor associated with PEP has not been studied in detail. The aim of this study was to determine the incidence of PEP in patients with CP at different clinical stages and to identify the predictive and protective factors of PEP in a large cohort. Methods: In this observational cohort study, medical records of patients with CP (CP group) and biliary diseases (BD group) in a tertiary hospital from January 2011 to May 2015 were examined. The difference in the incidence of PEP between CP group and BD group and the risk of PEP at different clinical stages of CP were calculated by the chi(2) test or the Fisher exact test. The predictive and protective factors for PEP were investigated by univariate and multivariate analysis. Results: In total, 2028 ERCP procedures were performed in 1301 patients with CP and 2000 procedures in 1655 patients with BD. The overall incidence of PEP in CP group (4.5%) was similar to that in the BD group (4.8%; P = .747). However, CP patients had significantly lower rates of moderate and severe attacks (0% vs 1.3%, P < .01). According to the M-ANNHEIM classification, the PEP incidences of CP at stages 0, I, II, III, and IV were 4.4%, 5.1%, 3.8%, 2.0%, and 2.0%, respectively. CP patients at stage Ia had the highest PEP incidence (8.0%) among all CP patients, significantly higher than that at stages Ib + Ic (3.9%) and II (3.8%). Female gender, history of acute pancreatitis, and prior PEP were independent risk factors of PEP, whereas extracorporeal shock wave lithotripsy was a protective factor. Conclusions: Compared with BD patients, CP patients had similar incidence of PEP overall but lower grades of severity. The incidence of PEP in CP patients decreased significantly with disease progression.
引用
收藏
页码:519 / U355
页数:7
相关论文
共 50 条
  • [31] Is endoscopic papillary balloon dilatation really a risk factor for post-ERCP pancreatitis?
    Fujisawa, Toshio
    Kagawa, Koichi
    Hisatomi, Kantaro
    Kubota, Kensuke
    Nakajima, Atsushi
    Matsuhashi, Nobuyuki
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (26) : 5909 - 5916
  • [32] Risk of post-ERCP pancreatitis with placement of self-expandable metallic stents
    Cote, Gregory A.
    Kumar, Nitin
    Ansstas, Michael
    Edmundowicz, Steven A.
    Jonnalagadda, Sreenivasa
    Mullady, Daniel K.
    Azar, Riad R.
    GASTROINTESTINAL ENDOSCOPY, 2010, 72 (04) : 748 - 754
  • [33] Post-ERCP Pancreatitis: Prevention, Diagnosis and Management
    Cahyadi, Oscar
    Tehami, Nadeem
    de-Madaria, Enrique
    Siau, Keith
    MEDICINA-LITHUANIA, 2022, 58 (09):
  • [34] Clinical Study on the Prevention of Post-ERCP Pancreatitis by Pancreatic Duct Stenting
    Pan, Xiao-Ping
    Dang, Tong
    Meng, Xian-Mei
    Xue, Kai-Cheng
    Chang, Zhi-Heng
    Zhang, Ya-Ping
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2011, 61 (03) : 473 - 479
  • [35] Rectal Indomethacin for the Prevention of Post-ERCP Pancreatitis
    Patai, Arpad V.
    Patai, Arpad
    GASTROENTEROLOGY, 2016, 151 (03) : 565 - 566
  • [36] Somatostatin administration prior to ERCP is effective in reducing the risk of post-ERCP pancreatitis in high-risk patients
    Zhao, Li-Na
    Yu, Tao
    Li, Chu-Qiang
    Lai, Yu
    Chen, Qi-Kui
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2014, 8 (02) : 509 - 514
  • [37] Post-ERCP pancreatitis: Reduction by routine antibiotics
    Sari Räty
    Juhani Sand
    Markku Pulkkinen
    Martti Matikainen
    Isto Nordback
    Journal of Gastrointestinal Surgery, 2001, 5 : 339 - 345
  • [38] Post-ERCP pancreatitis:: Reduction by routine antibiotics
    Räty, S
    Sand, J
    Pulkkinen, M
    Matikainen, M
    Nordback, I
    JOURNAL OF GASTROINTESTINAL SURGERY, 2001, 5 (04) : 339 - 345
  • [39] The effects of different mechanisms on the development of post-ERCP pancreatitis in an ERCP model in rats
    Bozkurt, Suleyman
    Guner, Ali
    Kadioglu, Huseyin
    Kece, Can
    Reis, Erhan
    Coskun, Halil
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2013, 24 (06) : 469 - 475
  • [40] ANALYSIS OF EFFECT OF INDOMETHACIN IN PREVENTION OF POST-ERCP PANCREATITIS PATIENTS
    Saba, Noreena
    Mazhar, Muhammad Usman
    Akber, Quratul Ain
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (01): : 50 - 53